ANI Pharmaceuticals Inc
ANIP82.850USD
+0.020+0.02%
Handelsschluss 12/19, 16:00（ET）Kurse um 15 Minuten verzögert
1.86BMarktkapitalisierung
48.51KGV TTM
mehr Informationen über ANI Pharmaceuticals Inc Unternehmen
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
ANI Pharmaceuticals Inc Informationen
BörsenkürzelANIP
Name des UnternehmensANI Pharmaceuticals Inc
IPO-datumMay 04, 2000
CEOLalwani (Nikhil Suresh)
Anzahl der mitarbeiter897
WertpapierartOrdinary Share
GeschäftsjahresendeMay 04
Addresse210 Main Street West
StadtBAUDETTE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl56623
Telefon12186343500
Websitehttps://www.anipharmaceuticals.com/
BörsenkürzelANIP
IPO-datumMay 04, 2000
CEOLalwani (Nikhil Suresh)
Führungskräfte von ANI Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
411.22K
-12.17%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+8.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+12.47%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
84.02K
-6.53%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
60.19K
-4.31%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
58.41K
-16.62%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
40.04K
-11.05%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
36.52K
-34.62%
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
25.16K
-6.68%
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
6.86K
-57.96%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
411.22K
-12.17%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+8.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+12.47%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
84.02K
-6.53%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
60.19K
-4.31%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
58.41K
-16.62%
Umsatzaufteilung
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Sales of generic pharmaceutical products
90.30M
0.00%
Sales of rare disease pharmaceutical products
81.65M
0.00%
Sales of Cortrophin Gel
81.65M
0.00%
Sales of branded pharmaceutical products
17.11M
0.00%
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Sales of generic pharmaceutical products
90.30M
0.00%
Sales of rare disease pharmaceutical products
81.65M
0.00%
Sales of Cortrophin Gel
81.65M
0.00%
Sales of branded pharmaceutical products
17.11M
0.00%
Aktionärsstatistik
Aktualisiert: Sun, Nov 16
Aktualisiert: Sun, Nov 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
10.43%
The Vanguard Group, Inc.
5.67%
Meridian Venture Partners
4.52%
State Street Investment Management (US)
3.17%
Esjay L.L.C,
2.82%
Andere
73.39%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
10.43%
The Vanguard Group, Inc.
5.67%
Meridian Venture Partners
4.52%
State Street Investment Management (US)
3.17%
Esjay L.L.C,
2.82%
Andere
73.39%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
41.11%
Investment Advisor/Hedge Fund
23.24%
Hedge Fund
19.41%
Individual Investor
7.45%
Research Firm
6.42%
Private Equity
4.52%
Corporation
2.84%
Pension Fund
1.67%
Bank and Trust
1.33%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
507
21.97M
100.49%
+14.84K
2025Q3
525
21.96M
103.27%
+407.79K
2025Q2
506
21.46M
110.44%
-446.10K
2025Q1
489
21.61M
106.49%
-1.37M
2024Q4
469
21.12M
108.93%
+156.97K
2024Q3
453
20.75M
88.54%
+3.60M
2024Q2
425
17.36M
85.19%
+1.07M
2024Q1
403
16.22M
82.13%
-1.01M
2023Q4
390
16.10M
82.95%
+39.70K
2023Q3
378
15.97M
79.12%
+734.26K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
2.37M
10.64%
-68.37K
-2.80%
Jun 30, 2025
The Vanguard Group, Inc.
1.27M
5.71%
+95.32K
+8.09%
Jun 30, 2025
Meridian Venture Partners
1.01M
4.55%
-150.00K
-12.88%
Aug 21, 2025
State Street Investment Management (US)
716.12K
3.21%
+1.55K
+0.22%
Jun 30, 2025
Esjay L.L.C,
632.62K
2.84%
-200.00K
-24.02%
Mar 14, 2025
Global Alpha Capital Management Ltd.
862.09K
3.87%
+126.50K
+17.20%
Jun 30, 2025
UBS Financial Services, Inc.
401.55K
1.8%
+137.16K
+51.88%
Jun 30, 2025
Citadel Advisors LLC
569.63K
2.56%
-153.70K
-21.25%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
553.89K
2.48%
-77.67K
-12.30%
Jun 30, 2025
Geode Capital Management, L.L.C.
427.55K
1.92%
-2.08K
-0.48%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Invesco Pharmaceuticals ETF
2.63%
State Street SPDR S&P Pharmaceuticals ETF
2.42%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.95%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.63%
Innovator IBD Breakout Opportunities ETF
1.38%
Innovator IBD 50 Fund ETF
1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
0.98%
Invesco S&P SmallCap Health Care ETF
0.96%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.92%
First Trust Small Cap Growth AlphaDEX Fund
0.67%
Mehr Anzeigen
Invesco Pharmaceuticals ETF
Anteil2.63%
State Street SPDR S&P Pharmaceuticals ETF
Anteil2.42%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil1.95%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Anteil1.63%
Innovator IBD Breakout Opportunities ETF
Anteil1.38%
Innovator IBD 50 Fund ETF
Anteil1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil0.98%
Invesco S&P SmallCap Health Care ETF
Anteil0.96%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Anteil0.92%
First Trust Small Cap Growth AlphaDEX Fund
Anteil0.67%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von ANI Pharmaceuticals Inc?
Die fünf größten Anteilseigner von ANI Pharmaceuticals Inc sind:
BlackRock Institutional Trust Company, N.A. hält 2.37M Aktien, was 10.64% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 1.27M Aktien, was 5.71% der Gesamtaktien entspricht.
Meridian Venture Partners hält 1.01M Aktien, was 4.55% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 716.12K Aktien, was 3.21% der Gesamtaktien entspricht.
Esjay L.L.C, hält 632.62K Aktien, was 2.84% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 2.37M Aktien, was 10.64% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 1.27M Aktien, was 5.71% der Gesamtaktien entspricht.
Meridian Venture Partners hält 1.01M Aktien, was 4.55% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 716.12K Aktien, was 3.21% der Gesamtaktien entspricht.
Esjay L.L.C, hält 632.62K Aktien, was 2.84% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von ANI Pharmaceuticals Inc?
Die drei wichtigsten Anteilseigner-Typen von ANI Pharmaceuticals Inc sind:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Meridian Venture Partners
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Meridian Venture Partners
Wie viele Institutionen halten Anteile an ANI Pharmaceuticals Inc (ANIP)?
Mit Stand vom 2025Q4 halten 507 Institutionen Anteile an ANI Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 21.97M, was 100.49% der Gesamtanteile entspricht. Im Vergleich zum 2025Q3 ist der institutionelle Aktienbesitz um -2.78% gestiegen.
Was ist die größte Einnahmequelle von ANI Pharmaceuticals Inc?
Am FY2025Q2 erzielte das Geschäft mit Sales of generic pharmaceutical products für ANI Pharmaceuticals Inc den höchsten Umsatz in Höhe von 90.30M, was --% des Gesamtumsatzes entspricht.
